• Patient has provided written informed consent

• Patient\* 18 years or older at time of signing the informed consent form

• Histologically or cytologically confirmed metastatic stage IV non-squamous NSCLC

• Negative local testing for TTF-1

• Negative molecular testing for EGFR mutations and ALK rearrangements (tested locally). Exception: In specific individual cases, treatment can be initiated prior to receiving molecular diagnostics after consulting with the sponsor, if the local principal investigator assesses the likelihood of an EGFR mutation or ALK fusion to be negligible. However, this should only be done in exceptional cases if the patient has particularly high demand for treatment. If it is subsequently found that patients are positive for EGFR mutations and/or ALK rearrangements, they must be withdrawn from the study immediately and must not receive any further study medication. Instead, patients should receive adequate SOC therapy outside the study.

• Awaiting results for molecular testing remains standard procedure for patient inclusion.

• PD-L1 tumor proportion score (TPS) \< 50%, tested locally by QUiP®-certified immunohistochemistry

• ECOG performance status ≤ 1

• Measurable lesions according to RECIST v1.1

• Life expectancy ≥ 12 weeks

⁃ Adequate hepatic, renal and bone marrow function

∙ Hemoglobin ≥ 8.0 g/dL

‣ Absolute neutrophil count ≥ 1.5 x 109/L

‣ Platelets ≥ 100 x 109/L

‣ Calculated creatine clearance ≥ 50 mL/min as determined by the Cockcroft-Gault equation and/or creatinin ≤ 1,5x upper limit of normal (ULN)

‣ Serum bilirubin ≤ 1.5 x institutional ULN

‣ AST/ ALT and alkaline phosphatase ≤ 2.5 x ULN

‣ International normalized ratio (INR)/ Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PTT is within therapeutic range of intended use of anticoagulants

⁃ The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.

⁃ Female patients who are considered as woman of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as up to 6 months after the last dose of study treatment. Male patients who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as at least 6 months after the last dose of IMP. Female patients who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic male patients do not require contraception